These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 17400300)

  • 1. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia.
    Cenci MA
    Trends Neurosci; 2007 May; 30(5):236-43. PubMed ID: 17400300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.
    Cenci MA; Lundblad M
    J Neurochem; 2006 Oct; 99(2):381-92. PubMed ID: 16942598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in understanding L-DOPA-induced dyskinesia.
    Cenci MA; Lindgren HS
    Curr Opin Neurobiol; 2007 Dec; 17(6):665-71. PubMed ID: 18308560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment.
    Crossman AR
    Mov Disord; 1990; 5(2):100-8. PubMed ID: 1970120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical physiology of dopa dyskinesia.
    Hallett M
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S147-50; discussion S150-3. PubMed ID: 10762142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic effects of levodopa and their possible role in dyskinesia.
    Mosharov EV; Borgkvist A; Sulzer D
    Mov Disord; 2015 Jan; 30(1):45-53. PubMed ID: 25450307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
    Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
    Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Prog Brain Res; 2008; 172():465-78. PubMed ID: 18772046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive association between striatal serotonin level and abnormal involuntary movements in chronic L-DOPA-treated hemiparkinsonian rats.
    Gil SJ; Park CH; Lee JE; Minn YK; Koh HC
    Brain Res Bull; 2011 Feb; 84(2):151-6. PubMed ID: 21163338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.
    Carta M; Carlsson T; Kirik D; Björklund A
    Brain; 2007 Jul; 130(Pt 7):1819-33. PubMed ID: 17452372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rodent models of treatment-induced motor complications in Parkinson's disease.
    Cenci MA; Ohlin KE
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S13-7. PubMed ID: 20123549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
    J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the serotonin system in L-dopa-induced dyskinesias.
    Carta M; Carlsson T; Muñoz A; Kirik D; Björklund A
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S154-8. PubMed ID: 18579429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
    García J; Carlsson T; Döbrössy M; Nikkhah G; Winkler C
    Neurobiol Dis; 2011 Sep; 43(3):576-87. PubMed ID: 21600983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
    Huot P
    J Neurol Sci; 2015 Apr; 351(1-2):9-12. PubMed ID: 25758471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.